[go: up one dir, main page]

RU2018130002A3 - - Google Patents

Download PDF

Info

Publication number
RU2018130002A3
RU2018130002A3 RU2018130002A RU2018130002A RU2018130002A3 RU 2018130002 A3 RU2018130002 A3 RU 2018130002A3 RU 2018130002 A RU2018130002 A RU 2018130002A RU 2018130002 A RU2018130002 A RU 2018130002A RU 2018130002 A3 RU2018130002 A3 RU 2018130002A3
Authority
RU
Russia
Application number
RU2018130002A
Other versions
RU2018130002A (ru
RU2743424C2 (ru
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of RU2018130002A publication Critical patent/RU2018130002A/ru
Publication of RU2018130002A3 publication Critical patent/RU2018130002A3/ru
Application granted granted Critical
Publication of RU2743424C2 publication Critical patent/RU2743424C2/ru

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D491/00Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/12Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
    • C07D491/20Spiro-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/04Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D217/00Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/22Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
    • C07D217/24Oxygen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D217/00Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/22Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
    • C07D217/26Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10Spiro-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D491/00Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10Spiro-condensed systems
    • C07D491/107Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06Animal cells or tissues; Human cells or tissues
    • C12N5/0602Vertebrate cells
    • C12N5/0652Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0658Skeletal muscle cells, e.g. myocytes, myotubes, myoblasts
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2509/00Methods for the dissociation of cells, e.g. specific use of enzymes
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2509/00Methods for the dissociation of cells, e.g. specific use of enzymes
    • C12N2509/10Mechanical dissociation

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Wood Science & Technology (AREA)
  • Rheumatology (AREA)
  • Zoology (AREA)
  • Urology & Nephrology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Child & Adolescent Psychology (AREA)
  • Cell Biology (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
RU2018130002A 2016-02-12 2017-02-10 Производные тетрагидроизохинолина RU2743424C2 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662285039P 2016-02-12 2016-02-12
US62/285,039 2016-02-12
PCT/US2017/017295 WO2017139526A1 (en) 2016-02-12 2017-02-10 Tetrahydroisoquinoline derivatives

Publications (3)

Publication Number Publication Date
RU2018130002A RU2018130002A (ru) 2020-03-12
RU2018130002A3 true RU2018130002A3 (ru) 2020-03-24
RU2743424C2 RU2743424C2 (ru) 2021-02-18

Family

ID=59561239

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2018130002A RU2743424C2 (ru) 2016-02-12 2017-02-10 Производные тетрагидроизохинолина

Country Status (34)

Country Link
US (5) US9914741B2 (ru)
EP (2) EP3413892B1 (ru)
JP (2) JP6832943B2 (ru)
KR (1) KR20180120701A (ru)
CN (2) CN113666938A (ru)
AR (1) AR107592A1 (ru)
AU (1) AU2017217663B2 (ru)
BR (1) BR112018016475A2 (ru)
CA (1) CA3012839A1 (ru)
CL (1) CL2018002287A1 (ru)
CO (1) CO2018007920A2 (ru)
CY (1) CY1125222T1 (ru)
DK (1) DK3413892T3 (ru)
ES (1) ES2913423T3 (ru)
HR (1) HRP20220655T1 (ru)
HU (1) HUE058820T2 (ru)
IL (1) IL261055B (ru)
LT (1) LT3413892T (ru)
MA (1) MA44018B1 (ru)
MD (1) MD3413892T2 (ru)
MX (1) MX379159B (ru)
NZ (1) NZ746311A (ru)
PH (1) PH12018501694B1 (ru)
PL (1) PL3413892T3 (ru)
PT (1) PT3413892T (ru)
RS (1) RS63240B1 (ru)
RU (1) RU2743424C2 (ru)
SG (1) SG11201806416XA (ru)
SI (1) SI3413892T1 (ru)
SM (1) SMT202200201T1 (ru)
TW (2) TWI719138B (ru)
UA (1) UA124879C2 (ru)
WO (1) WO2017139526A1 (ru)
ZA (1) ZA201804947B (ru)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI719138B (zh) * 2016-02-12 2021-02-21 日商安斯泰來製藥股份有限公司 四氫異喹啉衍生物
GB201905721D0 (en) 2019-04-24 2019-06-05 Univ Dundee Compounds
EP4240724A1 (en) 2020-11-06 2023-09-13 Cytokinetics, Inc. Bicyclic 1,4-diazepanones and therapeutic uses thereof
WO2025080100A1 (ko) * 2023-10-11 2025-04-17 한국화학연구원 신규한 디-아미드 화합물, 이의 제조방법, 이를 유효성분으로 포함하는 암 또는 자가면역질환의 예방 또는 치료용 약학적 조성물
CN117379425A (zh) * 2023-11-14 2024-01-12 广州日聚商贸发展有限公司 喹啉-4-羧酸在抗衰老产品以及保护肝脏、促进肝脏再生产品制备中的应用

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3301857A (en) 1963-08-26 1967-01-31 Hoffmann La Roche Spiro
SE368009B (ru) 1971-09-16 1974-06-17 Kabi Ab
CN1093130C (zh) * 1996-08-06 2002-10-23 辉瑞大药厂 被取代的吡啶并6,6-二环衍生物
CA2263479A1 (en) 1996-09-25 1998-04-02 Zeneca Limited Quinoline derivatives inhibiting the effect of growth factors such as vegf
US6410254B1 (en) 1999-05-18 2002-06-25 Cytokinetics Compositions and assays utilizing ADP or phosphate for detecting protein modulators
US6743599B1 (en) 1999-05-18 2004-06-01 Cytokinetics, Inc. Compositions and assays utilizing ADP or phosphate for detecting protein modulators
US7202051B1 (en) 1999-05-18 2007-04-10 Cytokinetics, Inc. Compositions and assays utilizing ADP or phosphate for detecting protein modulators
DE60024631T2 (de) * 1999-07-26 2006-06-14 Banyu Pharma Co Ltd Biaryl-harnstoff-derivate
JP2001106673A (ja) * 1999-07-26 2001-04-17 Banyu Pharmaceut Co Ltd ビアリールウレア誘導体
GB0321538D0 (en) 2003-09-13 2003-10-15 Glaxo Group Ltd Therapeutically useful compounds
BRPI0510365A (pt) 2004-04-28 2007-11-06 Takeda Pharmaceutical composto, método de produção de um composto, antagonista do receptor nk2, pró-droga, agente farmacêutico, métodos para antagonizar um recpetor nk2 e para evitar ou tratar doenças gastrintestinais funcionais, e, uso do composto ou uma pró-droga do mesmo
WO2007075783A2 (en) * 2005-12-22 2007-07-05 Wyeth Substituted isoquinoline-1,3(2h,4h)-diones, 1-thioxo-1,4-dihydro-2h-isoquinoline-3-ones and 1,4-dihydro-3(2h)-isoquinolones and use thereof as kinase inhibitor
GB0613208D0 (en) 2006-07-03 2006-08-09 Glaxo Group Ltd Compounds
ES2558517T3 (es) * 2006-08-02 2016-02-04 Cytokinetics, Inc. Ciertas entidades químicas, composiciones y métodos que comprenden imidazopirimidinas
RU2457203C2 (ru) 2006-12-27 2012-07-27 Санофи-Авентис Замещенные циклоалкиламином производные изохинолона
DK2097400T3 (da) 2007-01-05 2013-10-14 Daiichi Sankyo Co Ltd Kondenseret, substitueret aminopyrrolidinderivat
WO2008147547A1 (en) 2007-05-25 2008-12-04 Amgen Inc. Substituted hydroxyethyl amine compounds as beta-secretase modulators and methods of use
WO2009108332A1 (en) * 2008-02-27 2009-09-03 Vitae Pharmaceuticals, Inc. INHIBITORS OF 11β -HYDROXYSTEROID DEHYDROGENASE TYPE 1
CN101518971B (zh) * 2008-02-29 2012-07-18 E.I.内穆尔杜邦公司 聚酯叠层膜和使用该叠层膜的太阳能电池板
US8461182B2 (en) * 2008-10-02 2013-06-11 Taisho Pharmaceutical Co., Ltd. 7-piperidinoalkyl-3, 4-Dihydroquinolone derivative
JP5444365B2 (ja) 2008-10-29 2014-03-19 デシフェラ ファーマシューティカルズ,エルエルシー 抗癌活性および抗増殖活性を示すシクロプロパンアミドおよび類似物質
WO2010131147A1 (en) 2009-05-12 2010-11-18 Pfizer Limited Cyclobutenedione derivatives
AR081626A1 (es) 2010-04-23 2012-10-10 Cytokinetics Inc Compuestos amino-piridazinicos, composiciones farmaceuticas que los contienen y uso de los mismos para tratar trastornos musculares cardiacos y esqueleticos
US9133123B2 (en) 2010-04-23 2015-09-15 Cytokinetics, Inc. Certain amino-pyridines and amino-triazines, compositions thereof, and methods for their use
AR081331A1 (es) 2010-04-23 2012-08-08 Cytokinetics Inc Amino- pirimidinas composiciones de las mismas y metodos para el uso de los mismos
WO2011159760A1 (en) 2010-06-16 2011-12-22 Vitae Pharmaceuticals, Inc. Substituted 5-,6- and 7-membered heterocycles, medicaments containing such compounds, and their use
CA2827724A1 (en) * 2011-02-18 2012-08-23 Allergan, Inc. Substituted 6,7-dialkoxy-3-isoquinolinol derivatives as inhibitors of phosphodiesterase 10 (pde10a)
US8759380B2 (en) 2011-04-22 2014-06-24 Cytokinetics, Inc. Certain heterocycles, compositions thereof, and methods for their use
HUP1100241A3 (en) 2011-05-06 2013-12-30 Richter Gedeon Nyrt Oxetane substituted pyrimidones
AU2013243671B2 (en) 2012-04-02 2017-09-21 Cytokinetics, Inc. Methods for improving diaphragm function
EP2836590A4 (en) 2012-04-11 2016-04-13 Cytokinetics Inc METHOD FOR IMPROVING THE RESISTANCE TO SKELETON MUSCULAR FEEDING
AR091699A1 (es) 2012-07-10 2015-02-25 Astellas Pharma Inc Derivado de indol carboxamida
LT3137622T (lt) 2014-04-29 2022-04-25 Cytokinetics, Inc. Gyvybinio pajėgumo nykimo mažinimo būdai
US9987279B2 (en) 2014-09-09 2018-06-05 Astellas Pharma Inc. Pharmaceutical composition for prevention and/or treatment of urinary incontinence
TWI719138B (zh) 2016-02-12 2021-02-21 日商安斯泰來製藥股份有限公司 四氫異喹啉衍生物

Also Published As

Publication number Publication date
CA3012839A1 (en) 2017-08-17
JP6832943B2 (ja) 2021-02-24
HRP20220655T1 (hr) 2022-06-24
TW201741316A (zh) 2017-12-01
IL261055A (en) 2018-10-31
KR20180120701A (ko) 2018-11-06
EP3413892B1 (en) 2022-04-20
HUE058820T2 (hu) 2022-09-28
RS63240B1 (sr) 2022-06-30
MX2018009759A (es) 2018-11-29
US20170233402A1 (en) 2017-08-17
EP4032877A1 (en) 2022-07-27
NZ746311A (en) 2022-08-26
EP3413892A1 (en) 2018-12-19
EP3413892A4 (en) 2019-08-14
CO2018007920A2 (es) 2018-12-14
TWI773118B (zh) 2022-08-01
AU2017217663A1 (en) 2018-10-04
CN109069498A (zh) 2018-12-21
IL261055B (en) 2021-03-25
UA124879C2 (uk) 2021-12-08
CN109069498B (zh) 2021-08-17
MX379159B (es) 2025-03-10
US10259821B2 (en) 2019-04-16
RU2018130002A (ru) 2020-03-12
TW202138373A (zh) 2021-10-16
AR107592A1 (es) 2018-05-16
TWI719138B (zh) 2021-02-21
US20180148458A1 (en) 2018-05-31
JP7137650B2 (ja) 2022-09-14
JP2019509267A (ja) 2019-04-04
PL3413892T3 (pl) 2022-06-13
DK3413892T3 (da) 2022-05-23
US9914741B2 (en) 2018-03-13
WO2017139526A8 (en) 2018-08-16
MA44018B1 (fr) 2022-05-31
US10689393B2 (en) 2020-06-23
ES2913423T3 (es) 2022-06-02
PH12018501694A1 (en) 2019-01-28
BR112018016475A2 (pt) 2018-12-26
MD3413892T2 (ro) 2022-06-30
LT3413892T (lt) 2022-06-10
ZA201804947B (en) 2024-05-30
SI3413892T1 (sl) 2022-06-30
SMT202200201T1 (it) 2022-07-21
CY1125222T1 (el) 2025-03-28
RU2743424C2 (ru) 2021-02-18
US11479561B2 (en) 2022-10-25
SG11201806416XA (en) 2018-08-30
MA44018A (fr) 2018-12-19
CL2018002287A1 (es) 2019-01-04
US20200270266A1 (en) 2020-08-27
CN113666938A (zh) 2021-11-19
PT3413892T (pt) 2022-05-30
JP2021073270A (ja) 2021-05-13
PH12018501694B1 (en) 2023-08-30
AU2017217663B2 (en) 2021-06-17
US20230125280A1 (en) 2023-04-27
WO2017139526A1 (en) 2017-08-17
US20190194220A1 (en) 2019-06-27

Similar Documents

Publication Publication Date Title
BR112019009389A2 (ru)
BR122021013712A2 (ru)
BR122020022459A2 (ru)
BR112019009192A2 (ru)
BR112019006736A2 (ru)
BR202016025584U2 (ru)
BR202016021516U2 (ru)
CN303539494S (ru)
CN303539132S (ru)
CN303639092S (ru)
CN303633659S (ru)
CN303628681S (ru)
CN303626932S (ru)
CN303612650S (ru)
CN303609864S (ru)
CN303609244S (ru)
CN303604908S (ru)
CN303585021S (ru)
CN303580571S (ru)
CN303572583S (ru)
CN303564147S (ru)
CN303553112S (ru)
CN303550804S (ru)
CN303545345S (ru)
CN303700846S (ru)